ArticleThe Lancet regional health. Europe2024

Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom.

Vasantha Gowda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.